Revolution Medicines, Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a4eb72a9-c8d5-40c3-ae50-d0ad46a0ed03/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-1.2B | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-071563 |
| FY 2024 | $-689.5M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-027736 |
| FY 2023 | $-487.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-020145 |
| FY 2022 | $-258.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-004645 |
| FY 2021 | $-188.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002297 |
| FY 2020 | $-110.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-010276 |
| FY 2019 | $-54.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-010276 |
| FY 2018 | $-40.3M | 2018-01-01 – 2018-12-31 | evidence 0001564590-21-010276 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Revolution Medicines, Inc. — all facts · Revenue · Net Income